Leash Biosciences

Leash Biosciences is an AI-native biotech leveraging a unique data-generation engine to solve the core data gap in machine learning for drug discovery. The company's platform rapidly measures billions of protein-compound interactions, using this data to iteratively train models that design and test novel molecules, with a current capacity of screening 96 protein targets per week. While developing its own internal oncology programs, Leash also partners with biopharma companies, positioning itself as both a therapeutics developer and a platform technology provider. The company is led by a team with deep expertise in digital chemistry, laboratory automation, and data science, supported by advisors from top-tier institutions.

Integrated platform combining high-throughput screening of millions of compounds against thousands of proteins to generate billions of biochemical interaction data points. This proprietary dataset trains machine learning models in a closed-loop cycle to design, synthesize, and test novel molecules, with each iteration taking a few months.

Leash operates in the highly competitive AI/ML drug discovery sector, competing with well-funded public platforms (e.g., Recursion, Exscientia, Schrödinger) and internal big pharma efforts. Its differentiation is its intense focus on generating a proprietary, ultra-large-scale biochemical dataset as the foundation for its models, rather than relying primarily on public or curated data.